Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ERCC1 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

ERCC1 overexpression	Colorectal Cancer	ERCC1 overexpression	Colorectal Cancer	oxaliplatin Resistant: C3 – Early Trials oxaliplatin Resistant : C3	oxaliplatin Resistant: C3 – Early Trials oxaliplatin Resistant : C3
ERCC1 overexpression	Sarcoma	ERCC1 overexpression	Sarcoma	doxorubicin hydrochloride + trabectedin Sensitive: C3 – Early Trials doxorubicin hydrochloride + trabectedin Sensitive : C3	doxorubicin hydrochloride + trabectedin Sensitive: C3 – Early Trials doxorubicin hydrochloride + trabectedin Sensitive : C3
ERCC1 overexpression	Soft Tissue Sarcoma	ERCC1 overexpression	Soft Tissue Sarcoma	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3	trabectedin Sensitive: C3 – Early Trials trabectedin Sensitive : C3
ERCC1 overexpression	HER2 Positive Breast Cancer	ERCC1 overexpression	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
ERCC1 overexpression	Squamous Cell Carcinoma of Head and Neck	ERCC1 overexpression	Squamous Cell Carcinoma of Head and Neck	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials cisplatin + 5-fluorouracil Sensitive : C3	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials cisplatin + 5-fluorouracil Sensitive : C3
ERCC1 overexpression	Solid Tumor	ERCC1 overexpression	Solid Tumor	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
ERCC1 overexpression	Small Cell Lung Cancer	ERCC1 overexpression	Small Cell Lung Cancer	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3	cisplatin Sensitive: C3 – Early Trials cisplatin Sensitive : C3